SCZ 3.5
VUi011-A
General
Cell Line |
|
hPSCreg name | VUi011-A |
Cite as: | VUi011-A (RRID:CVCL_ZB12) |
Alternative name(s) |
SCZ 3.5
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
HDZi003-A (hiPSC NP0038) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 RNRMUi005-A (EB-iPSC-d4, RDEB-iPSC-d4) Donor diseases: Epidermolysis Bullosa Simplex recessive dystrophic epidermolysis bullosa UNIZARi001-A (FiPSTK2-2) Donor's gene variants: TK2, TK2 Donor diseases: Mitochondrial DNA depletion syndrome, myopathic form |
Last update | 20th November 2020 |
User feedback | |
Provider |
|
Generator | Vrije Universiteit Amsterdam (VU) |
External Databases |
|
Cellosaurus | CVCL_ZB12 |
BioSamples | SAMEA7762116 |
Wikidata | Q98134634 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA7762117 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Regional ethics board in Stockholm |
Approval number | 2011-324-31 and 2012/214-32 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Regional ethics board in Stockholm |
Approval number | 2011-324-31 and 2012/214-32 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
TeSR™ E8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SOX2 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
Pluripotency Score | Novelty Score | |
25,29 | 1,67 |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.